08Jul/13

Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma … – The Herald | HeraldOnline.com

Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma
The Herald | HeraldOnline.com
The European Medicines Agency’s (the EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled Phase 3 clinical trial, which compares PIXUVRI-rituximab to gemcitabine-rituximab in patients who 

and more »

07Jul/13

Safety last – Indian Express

Safety lastIndian ExpressNot too long ago, another popular painkiller in India, nimesulide, turned controversial for its link to liver toxicity. That drug was never approved in the US. When the Indian government sought to restrict its use, some doctors…